Charité begins implementation of MGN1601 clinical phase I/II study in renal cancer

The Charité - Medical University of Berlin has today begun the implementation of the clinical study phase I/II with the renal cancer medication MGN1601 (ASET Study). With this MOLOGEN AG product, an innovative cell-based gene therapy for the treatment of advanced renal cancer is entering the first important test phase.

MOLOGEN AG, which has since the outset been building its research activities on a diversified product pipeline, has also achieved a decisive milestone in an additional product segment with the start of the clinical study for the renal cancer medication MGN1601.

The primary goal of this study is the investigation of the safety and tolerability of the medication. In addition effectiveness data is recorded, which contain the clinical, immunological and radiological parameters of the patients.

As a leading research company in DNA medicine and cell-based medicine, MOLOGEN AG is consistently pursuing its goal of developing highly effective and safe medications for the treatment of cancer illnesses.

Therapeutic vaccination

The procedures developed by MOLOGEN AG for cell-based gene therapy against renal cancer involve a therapeutic vaccination to combat advanced tumors of the kidneys and the prevention of their reappearance after operations and medical treatment.

The basis of the therapy is human renal cancer cells. MOLOGEN itself has established a unique renal cancer cell line for this purpose. These cancer cells which are foreign (allogenic) for the patient are "gene-modified" with the help of MIDGE® DNA vectors with additional genetic information and combined with MOLOGEN's own DNA immune modulator dSLIM® as effectiveness enhancer (adjuvant).

The active principle of the cell-based gene therapy consists of provoking a cross-reaction of the immune system of the patients against their own cancer cells after the immune system has learned by the reaction against the gene-modified, foreign cancer cells how cancer cells typically appear. In preclinical investigations, the preparation has already exhibited outstanding tolerability and effectiveness.

Dr. Marina Tschaika, director of the clinical development department at MOLOGEN AG, explains: "With MGN1601 we hope to have developed a cancer therapy with few side effects, which will lead to long-term relief of cancer suffering and, at the same time, to a clear improvement in the quality of life for patients with advanced renal cancer. I am convinced that we are on the right track with this".

Study director PD Dr. Steffen Weikert, Charité Berlin

The clinical study is being directed by Dr. Steffen Weikert, assistant director of the clinic for Urology at the Charité of Berlin.

PD Dr. Steffen Weikert, an expert in the area of renal cancers, comments about the start of the study: "The ASET study with the preparation MGN1601 is an extremely interesting and promising study for us, because it builds on an advanced concept of therapeutic vaccination against renal cancer cells. We hope to continue to improve the prognosis for patients with advanced renal cancer with this therapeutic approach. This study will also open up to our patient perspectives for a better quality of life since the vaccination can be considered as low in side effects according to the current state of the art. We are pleased that the first patients can now be accepted for the study at Charite".


Charité Medical University of Berlin


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Hyperinsulinemic patients with breast cancer may be responsive to metabolism-targeting treatments